NSEGeneral Updates5 Jul 2026 · 5 Jul 2026, 02:10 pm

General Updates

Medplus Health Services Limited · MEDPLUS

✦ AI Summary▼ NegativeRegulatory

MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a drug license of a store in Maharashtra, which may impact revenue.

Analysis Scores

Earnings Impact6/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk8/10
Balance Sheet Risk0/10
Liquidity Impact5/10
Market Sentiment2/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Attachments (1)

📄

MEDPLUS_05072026141008_Intimation__3_.pdf

pdf

Download →
View document text
MedPlus Health Services Limited July 05, 2026 The Listing Department The Listing Department BSE Limited N ational Stock Exchange of India Limited Phiroze Jeejebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Fort, Plot No. C/1, G Block, Mumbai – 400001 Bandra - Kurla Complex BSE Scrip Code: 543427 Bandra (East), Mumbai – 400051 NSE Symbol: MEDPLUS Dear Sir/Madam, Sub: Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 We would like to inform you that Optival Health Solutions Private Limited, a subsidiary of the company, has received one suspension order for a Drug License of a store situated in the state of Maharashtra: Pursuant to SEBI Listing Regulations read along with SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026, the details of the matter are as follows: Name(s) of the Authority Nature and details of Date of receipt of Details of the Impact on the action(s) taken, direction or order, violation(s)/ financial initiated or order(s) including any interim contravention(s) operation or passed or interim orders, or committed or other activities of any other alleged to be the listed entity, communication from committed quantifiable in the authority monetary terms to the extent possible Asst. Commissioner & Suspension of Drug Order received on Under Rule 65 of Potential Revenue Licensing authority, Food & License for five days 04.07.2026 Drugs and Cosmetics Loss of Rs 0.75 Drug Administrations, of store situated at Act, 1940 and Drugs lacs. Nashik Maharashtra. Samta Nagar Nashik and Cosmetics Rules, Maharashtra 1945 The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively. Kindly take the same on records. For MedPlus Health Services Limited Gangadi Madhukar Reddy Managing Director and Chief Executive Officer DIN: 00098097 040-6724 672 Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com